Mateo Marin-Cuartas: What Matters After Aortic Valve Replacement in Younger Patients?
Mateo Marin-Cuartas, Cardiac Surgeon at German Heart Center of the Charité, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in EHJ – Valvular and Structural Heart Disease, adding:
“Beyond survival: how should we interpret patient-reported outcomes and health status after aortic valve replacement in younger patients?
In our new publication in the European Heart Journal – Valvular and Structural Heart Disease (EHJVSHD) from European Society of Cardiology, Milan Milojevic, Nikolaos Bonaros and I discuss the latest NOTION-2 health-status analysis comparing TAVI and SAVR in younger, low-risk patients.
Some important messages:
- At 3 years, patient-reported outcomes are similarly favorable after TAVI and SAVR. But for a younger patient, 3 years is a milestone-not the final destination.
- Quality of life matters. But so do durability, reintervention, major clinical events, coronary access, and future treatment options.
- The real challenge: achieving not only a good recovery today, but durable health and quality of life over a lifetime.
Special thanks to Prof. Marco Metra EiC of EHJVSHD, for the invitation to contribute with this editorial comment.”
Title: Beyond survival: how should we interpret patient-reported outcomes and health status after aortic valve replacement in younger patients?
Authors: Mateo Marin-Cuartas, Milan Milojevic, Nikolaos Bonaros

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 15:03Francesco Antonio Veneziano: Rethinking Coronary Artery Disease Through Precision Cardiology
-
Nov 15, 2026, 14:37Denise Rezende: 100 Years of von Willebrand Disease and Advances in Diagnosis
-
Nov 15, 2026, 14:22Ahmed Alotaibi: Does Donor Sex Influence Platelet Storage Quality
-
Nov 15, 2026, 14:09Stephen Alerhand: Acute Pulmonary Embolism vs Chronic Pulmonary Hypertension
-
Nov 15, 2026, 10:32Ibrahim Gwarzo: Identifying Care Gaps and Emergency Pain Delays in Sickle Cell Disease at APHA 2026
-
Nov 15, 2026, 10:17Ify Osunkwo: How the Sickle Cell Community Can Influence FDA Drug Development Priorities
-
Nov 15, 2026, 10:11Ahmed Abdelsalam: Why Matching ABO and RhD Groups Does Not Guarantee Crossmatch Compatibility
-
Nov 15, 2026, 10:06Asma Khalil: New British Society for Haematology Guidance on Paediatric and Neonatal Transfusion
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice